Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy

NCT03824080 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT03824080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Failing Standard of Care Therapy
Lead sponsor
GWT-TUD GmbH
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2018
Completion date
June 8, 2021
Enrollment
45 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, high-risk myelodysplastic syndrome, low-risk myelodysplastic syndrome